Build status - In Progress
Search filters
Filters
Clear All

Phase

  • 24
  • 4
  • 21
  • 1
  • 31
  • 1
  • 9
  • 94
  • 62
  • 1
  • 1
  • 92

Found 94 Vision Loss trials

A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

A Multicenter Randomized Double-Blind Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy

99 years or below
All genders
Phase 3
The trial will enroll subjects who have had an inadequate response (IR) to prior biologic therapy (bio-IR). The bio-IR population is defined as subjects with documented intolerance or inadequate response to one or more of the approved biologics for UC (infliximab, adalimumab, golimumab, and/or vedolizumab).
Learn More
ASPEN- A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis

ASPEN- A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis

18 years - 85 years
All genders
Phase 3
Interventional
Penn Medicine patients already participating in protocol INS1007 301 will be invited to participate in this study. The Pharmacokinetic (PK) portion of this substudy is designed to evaluate the amount of brensocatib present in your blood at certain time periods before and after the study drug is administered, and the …
Learn More
UPCC 05418: A Multicenter Double-Blind Randomized Placebo-Controlled Phase III Study of Idasanutlin an MDM2 Antagonist with Cytarabine Versus Cytarabine Plus Placebo in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

UPCC 05418: A Multicenter Double-Blind Randomized Placebo-Controlled Phase III Study of Idasanutlin an MDM2 Antagonist with Cytarabine Versus Cytarabine Plus Placebo in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

99 years or below
All genders
Phase 3
The purpose of this study is to compare the effects, good or bad, of idasanutlin plus cytarabine (chemotherapy) versus placebo (an inactive substance that looks like idasanutlin) plus cytarabine on patients with relapsed or refractory Acute Myeloid Leukemia (AML) to find out which is better.
Learn More

UPCC 03120: Randomized Double-Blind Phase 3 Study of Tucatinib or Placebo in Combination with Ado-Trastuzumab Emtansine (T-DM1) for Subjects with Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)

99 years or below
All genders
TBD
Learn More

A Randomized Double-blind Placebo-controlled Phase 1/2 Study to Evaluate the Safety Tolerability Pharmacokinetics Pharmacodynamics and Exploratory Efficacy of AOC 1020 Administered Intravenously to Adult Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

99 years or below
All genders
Phase 1
TBD
Learn More

A Multi-Center Randomized Double-blind Placebo-controlled Dose-finding Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CK-3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

99 years or below
All genders
Phase 2
Please see section 1 of the full protocol
Learn More

A Multicenter Randomized Double-Blind Placebo-Controlled Operationally Seamless Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata BRAVE-AA1

99 years or below
All genders
Phase 3
To evaluate the effectiveness of 4-mg baricitinib in significant increase in hair regrowth in patients with severe AA To describe the effectiveness of 4-mg baricitinib in achieving regrowth as assessed by physician assessed signs and symptoms of AA Mean percentage change from baseline to Week 52 in SALT score. Proportion …
Learn More

A Phase 3 Multicenter Randomized Double- Blind Placebo- Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene

99 years or below
All genders
Phase 3
The research study is being conducted to test the safety and tolerability (i.e., possible side effects) of an investigational drug called AL001 and to find out what effects AL001 has on the body. This is for people who have a confirmed progranulin gene mutation that causes frontotemporal dementia (FTD). Study …
Learn More

A Phase 2 Multicenter Randomized Double-Blind Placebo-Controlled Parallel Group Trial to Investigate the Efficacy and Safety of Daxdilimab Subcutaneous Injection in Reducing Disease Activity in Adult Participants with Moderate-to-Severe Primary Discoid Lupus Erythematosus

99 years or below
All genders
Phase 2
PURPOSE: Phase 2 study to evaluate effect of daxdilimab vs placebo to reduce DLE activity in adults 18-75 yo with DLE. 60 wks 99 pts multiple sites 3 trx grps: placebo; daxdilimab 150 mg; daxdilimab 300 mg. Randomize 1:1:1 sc injections q 4 wks Screening--4 wks; Treatment--48 wks; Follow-Up--8 wks. …
Learn More

HVTN 142: A Phase 1 Randomized Double-Blind Placebo-Controlled Clinical Study to Evaluate the Safety Reactogenicity and Immunogenicity of the HCMV-HIV Vaccine Candidate VIR-1388 in Adult Participants with Overall Good Health and Without HIV

99 years or below
All genders
The purpose of this study is to measure the safety, reactogenicity, and immunogenicity of VIR 1388 in adults in good health without HIV.
Learn More
41 - 50 of 94